CO6150192A2 - Anticuerpos monoclonales anti-il-6 y usos de los mismos - Google Patents
Anticuerpos monoclonales anti-il-6 y usos de los mismosInfo
- Publication number
- CO6150192A2 CO6150192A2 CO09007783A CO09007783A CO6150192A2 CO 6150192 A2 CO6150192 A2 CO 6150192A2 CO 09007783 A CO09007783 A CO 09007783A CO 09007783 A CO09007783 A CO 09007783A CO 6150192 A2 CO6150192 A2 CO 6150192A2
- Authority
- CO
- Colombia
- Prior art keywords
- seq
- amino acid
- acid sequence
- group
- sequence selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
1.- Un anticuerpo monoclonal aislado, el cual comprende: (a) una región variable de cadena pesada (VH) que comprende: (i) una VH-CDR1 que comprende una secuencia de aminoácidos seleccionada a partir del grupo que consiste en las: SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID N0:54, SEQ ID NO:55, y una secuencia de aminoácidos que es idéntica a cualquiera de las SEQ ID NOs: 51 a 55 excepto por 1 a 5 sustituciones de aminoácidos; (ii) una VH-CDR2 que comprende una secuencia de aminoácidos seleccionada a partir del grupo que consiste en las: SEQ ID NO:56, SEQ ID NO:57, SEQ ID N0:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID N0:61 SEQ ID NO:97, y una secuencia de aminoácidos que es idéntica a cualquiera de las SEQ ID NOs: 56 a 61 ó 97 excepto por 1 a 5 sustituciones de aminoácidos; (iii) una VH-CDR3 que comprende una secuencia de aminoácidos seleccionada a partir del grupo que consiste en las: SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO;71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:98, y una secuencia de aminoácidos que es idéntica a cualquiera de las SEQ ID NOs: 62 a 73 ó 98 excepto por 1 a 5 sustituciones de aminoácidos; y (b) una región variable de cadena ligera (VL) que comprende:(i) una VL-CDR1 que comprende una secuencia de aminoácidos seleccionada a partir del grupo que consiste en las: SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO: 79, y una secuencia de aminoácidos que es idéntica a cualquiera de las SEQ ID NOs: 74 a 79 excepto por 1 a 5 sustituciones de aminoácidos; (ii) una VL-CDR2 que comprende una secuencia de aminoácidos seleccionada a partir del grupo que consiste en las: SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, y una secuencia de aminoácidos que es idéntica a cualquiera de las SEQ ID NOs: 80 a 85 excepto por 1 a 5 sustituciones de aminoácidos; (iii) una VL-CDR3 que comprende una secuencia de aminoácidos seleccionada a partir del grupo que consiste en las: SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83510706P | 2006-08-03 | 2006-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6150192A2 true CO6150192A2 (es) | 2010-04-20 |
Family
ID=39033490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09007783A CO6150192A2 (es) | 2006-08-03 | 2009-01-28 | Anticuerpos monoclonales anti-il-6 y usos de los mismos |
Country Status (17)
Country | Link |
---|---|
US (1) | US7919095B2 (es) |
EP (1) | EP2064241B1 (es) |
JP (1) | JP2009545319A (es) |
KR (1) | KR101479537B1 (es) |
CN (1) | CN101563365B (es) |
AU (1) | AU2007282023B2 (es) |
BR (1) | BRPI0715115A2 (es) |
CA (1) | CA2657763C (es) |
CO (1) | CO6150192A2 (es) |
CR (1) | CR10563A (es) |
EA (1) | EA200900037A1 (es) |
IL (1) | IL196550A0 (es) |
MA (1) | MA30653B1 (es) |
MX (1) | MX2009001110A (es) |
NO (1) | NO20090224L (es) |
WO (1) | WO2008019061A2 (es) |
ZA (1) | ZA200900514B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
WO2008144763A2 (en) | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Antibodies to il-6 and use thereof |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
MX2010012031A (es) | 2008-05-13 | 2011-01-20 | Novimmune Sa | Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos. |
US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
JP2012503490A (ja) * | 2008-09-26 | 2012-02-09 | ワイス・エルエルシー | 単鎖抗体ライブラリー設計 |
BRPI0921665A2 (pt) * | 2008-11-13 | 2019-04-16 | Femta Pharmaceuticals, Inc. | humanizado anti-il-6 anticorpos |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
SG171804A1 (en) * | 2008-11-25 | 2011-07-28 | Alder Biopharmaceuticals Inc | Antibodies to il-6 and use thereof |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
EP2477647B1 (en) | 2009-09-14 | 2016-01-13 | The Regents of the University of Colorado | Modulation of yeast-based immunotherapy products and responses |
WO2011066369A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to raise albumin and/or lower crp |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
MY177062A (en) | 2010-03-12 | 2020-09-03 | Debiopharm Int Sa | Cd37-binding molecules and immunoconjugates thereof |
ES2847891T3 (es) | 2010-11-23 | 2021-08-04 | Vitaeris Inc | Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral |
US20120189621A1 (en) | 2011-01-21 | 2012-07-26 | Yann Dean | Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists |
CN103596590A (zh) * | 2011-04-01 | 2014-02-19 | 伊缪诺金公司 | Cd37结合分子及其免疫缀合物 |
WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
KR102321372B1 (ko) * | 2012-10-22 | 2021-11-11 | 원니스 바이오테크 컴퍼니 리미티드 | 인터류킨-6에 대한 항체 및 그의 용도 |
EP3489258A1 (en) * | 2012-11-08 | 2019-05-29 | Eleven Biotherapeutics, Inc. | Il-6 antagonists and uses thereof |
BR112017026027A2 (pt) | 2015-06-08 | 2018-08-14 | Debiopharm Int Sa | combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20 |
EP3888752A1 (en) | 2015-07-31 | 2021-10-06 | MedImmune Limited | Il-6 antibodies for use in treating cardiovascular diseases |
EP3341414A4 (en) | 2015-08-28 | 2019-03-27 | Debiopharm International SA | ANTIBODIES AND ASSAYS FOR DETECTION OF CD37 |
JP2019506863A (ja) * | 2016-02-02 | 2019-03-14 | カドモン コーポレイション,リミティド ライアビリティ カンパニー | Pd−l1及びkdrに対する二重結合タンパク質 |
SG11201809786TA (en) * | 2016-05-05 | 2018-12-28 | Univ Pennsylvania | Dna monoclonal antibodies targeting il-6 and cd126 |
US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
CA3051865C (en) | 2017-02-01 | 2023-01-17 | Yale University | Treatment of diuretic resistance |
CN111787950A (zh) | 2018-01-05 | 2020-10-16 | 科威迪亚治疗公司 | 用于无免疫抑制地治疗il-6介导的炎症的方法 |
CN109517064B (zh) * | 2018-10-10 | 2020-05-08 | 北京汇智和源生物技术有限公司 | 白介素-6的人源化单克隆抗体、其编码基因及应用 |
US20200405883A1 (en) | 2019-06-20 | 2020-12-31 | Baxalta Incorporated | Method of treatment with viral-based gene therapy |
CN112279913B (zh) * | 2020-10-30 | 2022-05-03 | 上海百英生物科技有限公司 | 一种抗人il-6单克隆抗体及应用 |
JP2023551542A (ja) | 2020-11-30 | 2023-12-08 | エニグマ バイオインテリジェンス,インコーポレイテッド | アルツハイマー病の非侵襲的評価 |
CN113980129B (zh) * | 2021-01-15 | 2023-07-28 | 东大生物技术(苏州)有限公司 | 一组il-11单克隆抗体及其医药用途 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2598666B2 (ja) * | 1987-10-19 | 1997-04-09 | 忠三 岸本 | 抗ヒトbcdfモノクローナル抗体 |
IL88375A (en) | 1988-11-14 | 1995-07-31 | Yeda Res & Dev | Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method |
DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
EP0399429A1 (en) * | 1989-05-22 | 1990-11-28 | Toray Industries, Inc. | Anti-human interleukin-6 monoclonal antibody |
JPH03139292A (ja) * | 1989-05-22 | 1991-06-13 | Toray Ind Inc | ヒトインタ―ロイキン―6に対するモノクロ―ナル抗体 |
JP2881311B2 (ja) | 1989-07-28 | 1999-04-12 | 味の素株式会社 | 抗ヒトbcdfモノクローナル抗体及びそれを用いたヒトbcdfの定量法 |
DE3939706C1 (es) * | 1989-12-01 | 1991-03-21 | Centre Regional De Transfusion Sanguine, Besancon, Fr | |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
JP3614183B2 (ja) * | 1993-05-31 | 2005-01-26 | 中外製薬株式会社 | ヒトインターロイキン−6に対する再構成ヒト抗体 |
AU6808194A (en) | 1993-05-31 | 1994-12-20 | Chugai Seiyaku Kabushiki Kaisha | Reconstructed human antibody against human interleukin-6 |
US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
DE69534075T2 (de) | 1994-06-07 | 2005-07-21 | Chugai Seiyaku K.K. | Vorbeugungs- und heilmittel für erkrankungen, die durch fibrin- oder thrombusbildung hervorgerufen werden |
HU223602B1 (hu) | 1994-10-07 | 2004-10-28 | Chugai Seiyaku Kabushiki Kaisha | Krónikus reumatoid artritisz kezelésére szolgáló, IL-6 receptor elleni antitestet tartalmazó gyógyszerkészítmény |
CN1075387C (zh) | 1994-12-29 | 2001-11-28 | 中外制药株式会社 | 含有il-6拮抗剂的抗肿瘤剂的作用增强剂 |
GB9702944D0 (en) | 1997-02-13 | 1997-04-02 | Univ Manchester | Reducing fibrosis |
ES2312184T3 (es) | 1997-03-21 | 2009-02-16 | Chugai Seiyaku Kabushiki Kaisha | Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas. |
PL201461B1 (pl) | 1998-03-17 | 2009-04-30 | Chugai Pharmaceutical Co Ltd | Czynnik zapobiegający lub terapeutyczny do leczenia zapalenia jelita, zawierający antagonistę IL-6 jako składnik aktywny |
US7494652B1 (en) | 1998-06-10 | 2009-02-24 | Promega Corporation | Treatment of sepsis |
DK1108435T3 (da) | 1998-08-24 | 2007-02-05 | Chugai Pharmaceutical Co Ltd | Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel |
US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
WO2000044774A2 (en) | 1999-01-27 | 2000-08-03 | The University Of South Florida | Inhibition of stat3 signal transduction for human cancer therapy |
US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
DE60141274D1 (de) | 2000-05-03 | 2010-03-25 | Medimmune Inc | Kombinationstherapie zur behandlung respiratorischer krankheiten mittels antikörper und anti-entzündungs wirkstoffe |
DK1334731T3 (da) | 2000-10-25 | 2008-05-26 | Chugai Pharmaceutical Co Ltd | Forebyggende eller terapeutisk middel mod psoriasis omfattende anti-IL-6-receptorantistof som aktiv bestanddel |
AU2000279625A1 (en) | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient |
US20050196755A1 (en) | 2000-11-17 | 2005-09-08 | Maurice Zauderer | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
US7858559B2 (en) | 2000-11-17 | 2010-12-28 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
EP1372720A4 (en) | 2001-03-02 | 2006-07-26 | Medimmune Inc | PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING ANTAGONISTS OF INTEGRIN ALPHA V BETA 3 |
AU2002322478A1 (en) | 2001-03-02 | 2002-12-16 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
WO2004039826A1 (en) * | 2001-11-14 | 2004-05-13 | Centocor, Inc. | Anti-il-6 antibodies, compositions, methods and uses |
JP4323317B2 (ja) | 2001-12-21 | 2009-09-02 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) | 可変領域配列のクローニング方法 |
US20060275294A1 (en) | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
US7482436B2 (en) * | 2002-08-30 | 2009-01-27 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human antihuman interleukin-6 antibody and fragment of antibody |
WO2004045507A2 (en) | 2002-11-15 | 2004-06-03 | Centocor, Inc. | Anti-angiogenic uses of il-6 antagonists |
EP1594897A4 (en) | 2003-02-04 | 2006-11-08 | Centocor Inc | USE OF IL-6 ANTAGONISTS IN COMBINATION WITH STEROIDS FOR INCREASED APOPTOSIS |
EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
JP4555924B2 (ja) | 2003-02-24 | 2010-10-06 | 中外製薬株式会社 | インターロイキン−6アンタゴニストを含有する脊髄損傷治療剤 |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
WO2005023193A2 (en) | 2003-09-04 | 2005-03-17 | Interleukin Genetics, Inc. | Methods of treating endometriosis |
BRPI0415765A (pt) | 2003-10-24 | 2006-12-26 | Medtronic Inc | técnicas para tratar desordens neurológicas pela atenuação da produção de mediadores pró-inflamatórios |
US20050100550A1 (en) | 2003-11-10 | 2005-05-12 | Mohit Trikha | Anti-angiogenic uses of IL-6 antagonists |
JP2008505054A (ja) | 2004-02-11 | 2008-02-21 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Il−6アンタゴニストで骨関節炎を治療する方法 |
CA2591587A1 (en) | 2004-12-16 | 2006-06-22 | Genentech, Inc. | Methods for treating autoimmune disorders |
EP1865982A1 (en) | 2005-04-06 | 2007-12-19 | Bioartificial Gel Technologies Inc. | Hydrogel composition for modulation of topical inflammatory response |
EP1712241A1 (en) | 2005-04-15 | 2006-10-18 | Centre National De La Recherche Scientifique (Cnrs) | Composition for treating cancer adapted for intra-tumoral administration and uses thereof |
PE20061324A1 (es) | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
EP2377884A1 (en) | 2005-05-10 | 2011-10-19 | Neoloch Aps | Neuritogenic peptides |
-
2007
- 2007-08-03 KR KR20097003512A patent/KR101479537B1/ko not_active IP Right Cessation
- 2007-08-03 JP JP2009522880A patent/JP2009545319A/ja active Pending
- 2007-08-03 WO PCT/US2007/017337 patent/WO2008019061A2/en active Application Filing
- 2007-08-03 EP EP07811042.6A patent/EP2064241B1/en active Active
- 2007-08-03 BR BRPI0715115-2A patent/BRPI0715115A2/pt not_active Application Discontinuation
- 2007-08-03 CA CA2657763A patent/CA2657763C/en not_active Expired - Fee Related
- 2007-08-03 US US11/882,751 patent/US7919095B2/en not_active Expired - Fee Related
- 2007-08-03 CN CN2007800289537A patent/CN101563365B/zh not_active Expired - Fee Related
- 2007-08-03 AU AU2007282023A patent/AU2007282023B2/en not_active Ceased
- 2007-08-03 MX MX2009001110A patent/MX2009001110A/es not_active Application Discontinuation
- 2007-08-03 EA EA200900037A patent/EA200900037A1/ru unknown
-
2009
- 2009-01-15 NO NO20090224A patent/NO20090224L/no not_active Application Discontinuation
- 2009-01-15 CR CR10563A patent/CR10563A/es unknown
- 2009-01-15 IL IL196550A patent/IL196550A0/en unknown
- 2009-01-22 ZA ZA200900514A patent/ZA200900514B/xx unknown
- 2009-01-28 CO CO09007783A patent/CO6150192A2/es unknown
- 2009-02-17 MA MA31649A patent/MA30653B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0715115A2 (pt) | 2013-06-04 |
KR101479537B1 (ko) | 2015-01-07 |
ZA200900514B (en) | 2010-04-28 |
IL196550A0 (en) | 2011-08-01 |
US20080075726A1 (en) | 2008-03-27 |
CN101563365A (zh) | 2009-10-21 |
KR20090039801A (ko) | 2009-04-22 |
AU2007282023A1 (en) | 2008-02-14 |
EP2064241B1 (en) | 2015-10-07 |
WO2008019061A2 (en) | 2008-02-14 |
CA2657763C (en) | 2016-05-31 |
CN101563365B (zh) | 2012-10-31 |
WO2008019061A3 (en) | 2008-10-09 |
US7919095B2 (en) | 2011-04-05 |
EA200900037A1 (ru) | 2009-10-30 |
NO20090224L (no) | 2009-03-31 |
MA30653B1 (fr) | 2009-08-03 |
MX2009001110A (es) | 2009-05-11 |
CA2657763A1 (en) | 2008-02-14 |
AU2007282023B2 (en) | 2012-09-13 |
CR10563A (es) | 2009-04-14 |
JP2009545319A (ja) | 2009-12-24 |
EP2064241A2 (en) | 2009-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6150192A2 (es) | Anticuerpos monoclonales anti-il-6 y usos de los mismos | |
CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
RS52713B (en) | MONGLONAL ANTIBODIES BINDING HGM-CSF AND MEDICAL COMPOSITIONS CONTAINING THE SAME | |
AR073232A1 (es) | Anticuerpos anti-il-17a/f biespecificos y con reactividad cruzada | |
AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) | |
AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
PE20141659A1 (es) | Dominios variables singulares anti-vgf fusionados con dominios de fc | |
PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
PE20141162A1 (es) | Anticuerpos anti-il-23 | |
NZ603529A (en) | Antibodies to human gdf8 | |
NZ600512A (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
AR095432A1 (es) | Proteínas de unión a antígeno | |
PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
CO6190543A2 (es) | Anticuerpos anti-factor d humanizados | |
EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
PE20081478A1 (es) | Anticuerpos cd44 | |
PE20180502A1 (es) | Composiciones anti-cgrp y uso de las mismas | |
CO6362024A2 (es) | Anticuerpos humanos de alta afinidad para el receptor il-4 humano | |
FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
PE20080035A1 (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina | |
PE20191408A1 (es) | Proteinas de union a antigeno st2 | |
PE20140825A1 (es) | Anticuerpos contra il-6 y sus usos | |
CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. |